Regulus Therapeutics Inc (RGLS) concluded trading on Wednesday at a closing price of $0.97, with 4.38 million shares of worth about $4.25 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -46.99% during that period and on January 29, 2025 the price saw a loss of about -17.09%. Currently the company’s common shares owned by public are about 65.50M shares, out of which, 52.66M shares are available for trading.
Stock saw a price change of -21.77% in past 5 days and over the past one month there was a price change of -39.38%. Year-to-date (YTD), RGLS shares are showing a performance of -38.61% which decreased to -23.02% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.13 but also hit the highest price of $3.79 during that period. The average intraday trading volume for Regulus Therapeutics Inc shares is 341.75K. The stock is currently trading -27.63% below its 20-day simple moving average (SMA20), while that difference is down -33.87% for SMA50 and it goes to -44.59% lower than SMA200.
Regulus Therapeutics Inc (NASDAQ: RGLS) currently have 65.50M outstanding shares and institutions hold larger chunk of about 69.96% of that.
The stock has a current market capitalization of $63.54M and its 3Y-monthly beta is at 1.58. It has posted earnings per share of -$1.08 in the same period. It has Quick Ratio of 13.65 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RGLS, volatility over the week remained 11.67% while standing at 9.12% over the month.
Stock’s fiscal year EPS is expected to rise by 46.10% while it is estimated to decrease by -45.40% in next year. EPS is likely to shrink at an annualized rate of -0.36% for next 5-years, compared to annual growth of 50.96% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on August 02, 2024 offering an Outperform rating for the stock and assigned a target price of $7 to it. Coverage by Leerink Partners stated Regulus Therapeutics Inc (RGLS) stock as an Outperform in their note to investors on March 18, 2024, suggesting a price target of $6 for the stock. On March 28, 2018, B. Riley FBR Inc. Initiated their recommendations, while on January 05, 2018, Leerink Partners Initiated their ratings for the stock with a price target of $2. Stock get a Buy rating from Chardan Capital Markets on June 13, 2017.
